Skip to main content

THE PITCH: TNeuroPharma received VC funding to commercialize a potential deterrent for Alzheimer's disease

The company is commercializing two T-cell products which are meant to work in conjunction, according to Kristina Trujillo, CEO of the startup.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.